Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition

(MedPage Today) -- CHICAGO -- Single-agent dostarlimab (Jemperli) led to complete responses in 100% of a small group of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, allowing them to avoid surgery, chemotherapy...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news